Eli Lilly and Company successfully completed its acquisition of Verve Therapeutics in an all-cash transaction valued at approximately $1 billion upfront, with additional contingent value rights that could push the total valuation even higher. This strategic buyout brought Verve's pioneering cardiovascular gene-editing pipeline directly in-house, allowing the pharmaceutical giant to leverage its massive global clinical, regulatory, and commercial infrastructure to accelerate the development of innovative one-time treatments targeting chronic heart disease.